H. Lundbeck AS (FRA:LDBA) Other Current Payables: €314 Mil (As of Mar. 2026)


FRA:LDBA H. Lundbeck AS FRA:LDBA
81 GF Score
Price €5.93
GF Value €6.31
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is H. Lundbeck AS Other Current Payables?

H. Lundbeck AS FRA:LDBA +3.13% 81 Other Current Payables is €314 Mil as of Mar. 2026. GuruFocus rates FRA:LDBA with a GF Score™ of 81/100 and a GF Value™ of €6.31 (Fairly Valued). The stock has 4 warning signs investors should review.

H. Lundbeck AS's Other Current Payables for the quarter that ended in Mar. 2026 was €314 Mil.

H. Lundbeck AS's quarterly Other Current Payables declined from Sep. 2025 (€303 Mil) to Dec. 2025 (€276 Mil) but then increased from Dec. 2025 (€276 Mil) to Mar. 2026 (€314 Mil).

H. Lundbeck AS's annual Other Current Payables increased from Dec. 2023 (€260 Mil) to Dec. 2024 (€282 Mil) but then declined from Dec. 2024 (€282 Mil) to Dec. 2025 (€276 Mil).

H. Lundbeck AS Other Current Payables Related Terms

H. Lundbeck AS Other Current Payables Historical Data

* Premium members only.

The historical data trend for H. Lundbeck AS's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

H. Lundbeck AS Other Current Payables Chart

H. Lundbeck AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 356.37 267.22 259.88 281.86 276.48

H. Lundbeck AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 277.80 268.63 303.07 276.48 314.28
FRA:LDBA
81GF Score
H. Lundbeck AS FRA:LDBA
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

H. Lundbeck AS Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of €314 Mil mean?
H. Lundbeck AS (FRA:LDBA) has a Other Current Payables of €314 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Other Current Payables too high?
H. Lundbeck AS's current Other Current Payables is €314 Mil. Overall, H. Lundbeck AS has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Other Current Payables compare to ZTS and UTHR?
H. Lundbeck AS's Other Current Payables of €314 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Other Current Payables is €314 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €6.31, compared to a current price of €5.93 — trading 6.1% below its estimated fair value. The current Other Current Payables is €314 Mil. H. Lundbeck AS's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current Other Current Payables is €314 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?

Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued. The current stock price of €5.93 is trading 6.1% below its estimated GF Value™ of €6.31. GuruFocus considers H. Lundbeck AS to be Fairly Valued.

Key valuation signals for FRA:LDBA:

  • Other Current Payables: €314 Mil
  • GF Value™: €6.31 vs. price of €5.93 (6.1% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

H. Lundbeck AS Business Description

Address Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
81GF Score

Get the complete analysis for FRA:LDBA

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.93
Price
€6.31
GF Value